drugset / Trial / NCT01217892

Evaluation of Dapagliflozin Taken Twice-daily

NCT01217892

Phase 3 Completed 400 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being carried out to see if dapagliflozin - administered in a daily dose of 2.5 mg given twice a day or 5 mg twice a day or 10mg once daily - in addition to metformin, is beneficial in diabetes treatment, and if so, how it compares to treatment with metformin alone.

Timeline

Start
2010-11
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 2.5 mg Oral
Subject Dapagliflozin Small molecule 5 mg Oral
Subject Dapagliflozin Small molecule 10 mg Oral
Background Metformin Small molecule 1500 mg Oral